Novel Therapies for Prevention and Early Treatment of Cardiomyopathies
Tóm tắt
Heritable cardiomyopathies are a class of heart diseases caused by variations in a number of genetic loci. Genetic variants on one allele lead to either a degraded protein, which causes a haploinsufficiency of that protein, or a nonfunctioning protein that subverts the molecular system within which the protein works. Over years, both of these mechanisms eventually lead to diseased heart tissue and symptoms of a failing heart. Most cardiomyopathy treatments repurpose heart failure drugs to manage these symptoms and avoid adverse outcomes. There are few therapies that correct the underlying pathogenic genetic or molecular mechanism. This review will reflect on this unmet clinical need in genetic cardiomyopathies and consider a variety of therapies that address the mechanism of disease rather than patient symptoms. These therapies are genetic, targeting a defective gene or transcript, or ameliorating a genetic insufficiency. However, there are also a number of small molecules under exploration that modulate downstream faulty protein products affected in cardiomyopathies.
Từ khóa
Tài liệu tham khảo
MyoKardia Inc. Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM). Available at: https://clinicaltrials.gov/ct2/show/NCT03470545. Accessed March 6 2019.
Heart Metabolics Limited. Efficacy Safety and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure. Available at: https://clinicaltrials.gov/ct2/show/NCT02431221. Accessed March 6 2019.
The University of Texas Health Science Center Houston. Hypertrophic Regression With N-Acetylcysteine in HCM (HALT). Available at: https://clinicaltrials.gov/ct2/show/NCT01537926. Accessed March 6 2019.
McNally EM Mestroni L. Genetic Determinants and Mechanisms. 18
Prowse, C. Rocket Pharmaceuticals Announces Preclinical Data for AAV-Based RP-A501, the First Investigational Gene Therapy Program for a Monogenic Heart Failure Syndrome. Rocket Pharma, 2018.
Phrixus Pharmaceuticals Inc. Safety and Efficacy of P-188 NF in DMD Patients. Available at: https://clinicaltrials.gov/ct2/show/NCT03558958. Accessed April 1 2019.
Klein, CJ, Coovert, DD, Bulman, DE, Ray, PN, Mendell, JR, Burghes, AH. Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet. 1992;50:950–959.
National Academies of Sciences, Engineering, and Medicine, National Academy of Medicine, National Academy of Sciences & Committee on Human Gene Editing: Scientific, Medical, and Ethical Considerations. Human Genome Editing: Science, Ethics, and Governance. Washington, DC: The National Academies Press. https://doi.org/10.17226/24623.
International Bioethics Committee. Report of the International Bioethics Committee (IBC) on Updating Its Reflection on the Human Genome and Human Rights. FINAL RECOMMENDATIONS. Rev Derecho Genoma Hum. 2015;195–199.